Source link : https://www.newshealth.biz/health-news/antibody-drug-conjugate-shows-promising-activity-in-extensive-stage-sclc/
Treatment with the antibody drug-conjugate ifinatamab deruxtecan (I-DXd) showed promising activity in pretreated patients with extensive-stage small cell lung cancer (SCLC), particularly those treated at a higher dose, according to an interim analysis of the phase II IDeate-Lung01 study. In the dose optimization part of the study, which evaluated two doses, the cohort of patients […]
Author : News Health
Publish date : 2024-09-11 19:40:01
Copyright for syndicated content belongs to the linked Source.
Categories